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lack of efficiency (n = 1) and side effects (n = 1). These data 
confirm and expand previous reports on the good effects 
and tolerability of SO as a treatment for narcolepsy with cat-
aplexy.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Narcolepsy with cataplexy (NC) is a disabling life-long 
sleep-wake disorder, characterized by excessive daytime 
sleepiness (EDS) and sudden loss of muscle tone triggered 
by emotions (cataplexy)  [1] . Additional symptoms in-
clude sleep paralysis, hypnagogic hallucinations and 
fragmented nighttime sleep. Cataplexy is specific for nar-
colepsy and its presence allows diagnosing NC on clinical 
grounds. Typical paraclinical findings with diagnostic 
significance include the occurrence of two or more sleep-
onset REM periods (SOREMPs) in the multiple sleep la-
tency test (MSLT)  [2] , association to the HLA-DQB1 * 0602 
(found in 98% of NC compared to 35% of healthy con-
trols)  [3] and decrease of CSF hypocretin (levels  ! 110 pg/
ml are considered low or undetectable, between 110 and 
200 pg/ml intermediate and levels  1 200 pg/ml are con-
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 Abstract 
 Sodium oxybate (SO; Xyrem) has been approved in most 
countries for treatment of narcolepsy and cataplexy. In this 
study, we present a single-center experience of a series of 18 
patients with narcolepsy with cataplexy (18/18 DQB1*0602 
positive, 17/17 with low/absent cerebrospinal fluid hypocre-
tin) in whom SO was prescribed. After 26 ± 13 months, 13/18 
patients were still on SO at a mean dosage of 6.1 ± 1.2 g (in 8 
of them in combination with stimulants). The following sig-
nificant effects were observed: improved subjective sleepi-
ness (12/13), cataplexy (13/13; median number of attacks 
from 20 to 1/month), hallucinations (8/10) and sleep paralysis 
(8/8); increase in mean sleep latency on the Maintenance of 
Wakefulness Test (from 5.5 to 17.4 min) and sleep/rest effi-
ciency on actigraphy (from 61 to 76%); decrease in Epworth 
Sleepiness Scale score (from 18 to 14), sleep onset REM peri-
ods on the Multiple Sleep Latency Test (from 3.6 to 2.4) and 
errors in the Steer-Clear Test (from 11 to 2%). Five patients 
discontinued SO because of insufficient compliance (n = 2), 
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sidered normal)  [4] . The conventional treatment is symp-
tomatic and includes stimulant drugs (amphetamine an-
alogs and modafinil) targeting EDS and antidepressants 
to treat cataplexy  [5] . Sodium oxybate (SO), also known 
as   -hydroxybutyrate (GHB), is a new approach to treat 
all symptoms of the disease. It has been suggested that 
GHB has a role as a neurotransmitter or neuromodulator 
in the mammalian brain  [6] and specific high-affinity 
binding sites have been identified in hippocampus, ven-
trolateral thalamus and the frontoparietal and entorhinal 
cortex of the rat brain  [7] .
 GHB was first synthesized in 1960 and was shown to 
cross the blood-brain barrier rapidly to induce a sleep-
like state with cardiovascular stability. In 1964, the sub-
stance was introduced as an intravenous anesthetic but 
was never largely accepted because of the high incidence 
of side effects (vomiting, seizures). In 1967, it was hy-
pothesized that GHB might be beneficial for the treat-
ment of sleep disorders  [8] . Broughton and Mamelak  [9, 
10] decided to use GHB to normalize nighttime sleep in 
narcolepsy patients and thus to improve the daytime 
symptoms of the disease. These and following studies 
 [11–13] demonstrated that the bedtime administration of 
GHB improved nighttime sleep but also daytime sleepi-
ness, cataplexy, hypnagogic hallucinations and sleep pa-
ralysis. Parallel to these studies, reports appeared that 
GHB enhanced the effect of steroids and the release of 
growth hormone  [14] . As a consequence, the drug was 
used by bodybuilders and for strength training. After the 
reports of a few fatal overdose cases in bodybuilders, 
GHB was banned by the American Food and Drug Ad-
ministration (FDA) in 1990. This was followed by illicit 
use of GHB as a recreational drug because of its euphor-
ic effects, disinhibition and sexual arousal. It was also 
implicated in a number of sexual assault cases and was 
labeled as ‘date rape drug’. Especially in combination 
with alcohol GHB, causes anterograde amnesia and the 
victims are unable to recall any details of the event. In 
Switzerland, mainly cases with acute GHB intoxication 
have been reported  [15–17] . According to the GHB fact-
sheet, issued by the Swiss National Health Organization 
(Bundesamt für Gesundheit, BAG) between 1997 und 
2005, 334 cases with GHB intoxication were reported to 
the Swiss Toxicological Information Centre, of which 
only 1 was fatal  [18] . Recently, 3 fatal cases in patients 
with NC (n = 2) and sleep apnea (n = 1) treated with SO 
were reported  [19] , but the link with SO was not clear in 
any of them  [20] .
 In 1994, Orphan Medical began the development of 
SO oral solution and after the safety and the efficacy of 
the drug for the treatment of narcolepsy were estab-
lished in two multicenter, double-blind, placebo-con-
trolled, randomized trials  [21, 22] , the FDA approved it 
for the treatment of cataplexy in narcolepsy in 2002 and 
for the treatment of EDS in 2005. In 2005, SO was also 
approved by the European Medicines Agency (EMEA). 
Swissmedic approved it in Switzerland in 2006. In the 
mean time, the long-term efficacy  [23] and the effect of 
SO on daytime alertness have been shown  [24–27] . 
Based on A-level evidence, SO has been recommended 
as a first-line treatment for cataplexy in NC by the Eu-
ropean Federation of Neurological Societies (EFNS) 
Task Force  [28] .
 In this study, we present our own experience in the 
treatment of NC patients with SO.
 Patients and Methods 
 Eighteen HLA-DQB1 * 0602-positive (18/18), hypocretin-defi-
cient (17/17) NC patients (9 men), mean age 43 years  8 16 (SD), 
mean disease duration 14  8 14 years, were treated with SO be-
cause of persistent/severe cataplexy (n = 18/18) and EDS (n = 
18/18). Disturbed nighttime sleep was reported in 17/18 patients. 
The Epworth sleepiness score (ESS), frequency of cataplexy, sleep 
paralysis, hallucinations and nightmares were assessed before 
and after treatment. Video-polysomnography (PSG) was per-
formed in 17/18 patients before treatment and in 6/18 patients af-
ter treatment, MSLT in 16/18, respectively in 10/18, maintenance 
of wakefulness test (MWT) and actigraphy in 15/18, respectively 
in 10/18, and steer-clear vigilance test (SCVT) in 14/18, respec-
tively in 10/18 patients.
 PSG consisted of four-channel EEG (C3/A2, C4/A1, O1/A2, 
O2/A1), left and right electrooculography (EOG), submental elec-
tromyography (EMG), electrocardiography (ECG), respiratory 
flow and effort, pulse oximetry and left and right anterior tibialis 
EMG. All recordings were done on Embla Somnologica TM Studio. 
Sleep stages, apneas/hypopneas, periodic limb movements and 
arousals were scored manually according to international criteria 
 [2, 29–31] . Sleep onset was defined as the first epoch of either 
NREM-2 or REM sleep.
 Standard MSLT  [32] was performed on the day following the 
nocturnal recording, starting 2 h after waking up. For each pa-
tient, four or five naps with a duration of 20 min in 2-hour inter-
vals were recorded. The naps were terminated after 20 min. MWT 
was performed at daytime, for each patient four naps, each with a 
maximal duration of 40 min in 2-hour intervals were recorded. In 
case the patient fell asleep, the recording was interrupted after 
three consecutive epochs of NREM-1 or after one epoch of any 
other sleep stage. Sleep onset for both MSLT and MWT was de-
fined as the first epoch of sleep.
 Fourteen-day actigraphy was performed using Actiwatch  
(Cambridge Neurotechnology); the main parameter of interest 
was the sleep/rest efficiency in percent. Vigilance during a mo-
notonous task was assessed using the steer-clear vigilance test 
(SCVT) computer program  [33] . For SCVT an arbitrary cut-off of 
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3% has been accepted in different sleep laboratories as normal 
controls usually lie clearly below this value  [33] .
 Statistical analysis was performed using SPSS 15 software.   2 , 
paired t tests and Wilcoxon signed rank tests were used to analyze 
categorical and continuous variables, respectively. Significance 
level was set at p  ! 0.05.
 Results 
 All patients were HLA-DQB1 * 0602-positive and in 
17/18, CSF levels of hypocretin-1 were measured. It was 
undetectable in 13, low in 3, and intermediate in 1 patient. 
ESS was assessed in all patients at baseline. All patients 
reported cataplexy with a monthly frequency ranging 
form 1 to 600 (median 16, mean 101). Sleep paralysis was 
reported in 11/18 patients, hypnagogic hallucinations in 
14/18, nightmares in 4/18 and disturbed nighttime sleep 
in 17/18 patients. The demographics, ESS, PSG, MSLT, 
MWT, actigraphy and SCVT data for all patients prior to 
treatment are shown in  table 1 .
 Patients on Sodium Oxybate 
 Thirteen out of 18 patients are still treated with SO (7 
men, mean dosage 6.4  8 1.2 g, mean treatment duration 
26  8 13 months). Additional therapies include modafinil 
(n = 5), fluoxetine (n = 1) and methylphenidate (n = 1). 
One patient stopped modafinil after the initiation of SO, 
in all the others the additional therapies remained stable.
 One patient reported overall improvement of the nar-
colepsy symptoms of about 80% with one single bedtime 
dose of 5 g SO. Another 2 patients admitted skipping the 
second dose occasionally but in spite of that did not no-
tice any significant difference in their symptoms. The 
remaining 10 patients reported taking SO regularly
twice – at bedtime and between 2.5 and 4 h later.
 Nearly all patients (12/13) reported subjective im-
provement in EDS (from 20 to 80%, mean 33  8 23%). ESS 
significantly improved (from 17.9 to 13.9, p = 0.001). After 
treatment, 6/13 patients were free of cataplexy, in 7/13 pa-
tients a marked reduction in cataplexy frequency, dura-
tion and severity was observed. Cataplexy under SO usu-
ally occurred later in the day, when the patients were 
tired. In general the improvement of cataplexy was high-
ly significant (median before treatment 20 per month, af-
ter treatment 1, p = 0.001). The reduction in percent was 
between 50 and 100%, mean  8 SD, 88  8 19%. Sleep pa-
ralyses disappeared in 8/8 patients after initiation of SO. 
Under SO treatment, 8/10 patients were free of hallucina-
tions, 2 patients reported significant reduction in the fre-
quency of hallucinations. Nightmares disappeared in 3 
Table 1.  Characteristics of the patients prior to treatment with SO
Variable Mean 8 SD Range
Age, years 43816 18–69
Male gender 9
Disease duration, years 14814 2–50
ESS 1784 9–24
Cataplexy frequency per month, median 16 1–600
Sleep paralysis per month 589 0–30
Hallucination frequency per month 788 0–30
Sleep/rest efficiency in actigraphy, % 62819 16–81
Rest/sleep for 24 h, % 37812 10–72
Sleep latency, min 8810 0–38
Sleep efficiency, % 8889 71–98
REM latency, min 35862 0–232
Apnea/hypopnea index/h 11818 0–68
PLMS index/h 15824 0–70
NREM-1, % 1886 9–31
NREM-2, % 36810 19–54
Slow wave sleep, % 1287 0–22
REM, % 2188 12–38
Arousal index/h 1687 7–32
Mean sleep latency in MSLT 1.881.2 0.4–4.6
Number of SOREM in MSLT 3.680.7 2–4
Mean sleep latency in MWT 6.384.1 0.5–15.8
Number of SOREM in MWT 1.181.2 0–3
Error % in SCVT 8.589.7 0.6–37.8
E SS = Epworth sleepiness score; MSLT = multiple sleep la-
tency test; MWT = maintenance of wakefulness test; SOREM = 
sleep-onset REM period; SCVT = steer-clear vigilance test.
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 Fig. 1. Improvement of clinical symptoms after treatment, in per-
cent. 
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and persisted in 1 of 4 patients. All patients experienced 
a subjective improvement of their nighttime sleep. The 
improvement of the clinical symptoms of NC is presented 
in  figure 1 .
 Rest/sleep efficiency in the actigraphy improved (from 
61 to 76%, p = 0.017), the mean sleep latency in MSLT did 
not differ significantly, the mean sleep latency in MWT 
increased clearly (from 5.5 to 17.4 min, p  ! 0.001) and the 
error quotient in SCVT decreased (from 10.7 to 2.1%, p = 
0.017). In PSG a decrease in sleep latency, REM sleep la-
tency, apnea/hypopnea index, NREM-1, REM and arous-
al index and an increase in slow wave sleep was observed, 
although as PSG was available before and after treatment 
in only 5 patients, the results did not reach statistical sig-
nificance. The results of the different tests are presented 
in  table 2 . An actigraphy and a PSG hypnogram example 
before and after treatment are shown in  figure 2 .
 Dropouts 
 In 5 patients the drug was discontinued shortly after 
initiation due to insufficient compliance (n = 2), lack of 
efficiency (n = 2) or side effects (n = 1), including nausea 
and worsening of sleepiness and cataplexy. This patient 
did not tolerate modafinil and fluoxetine either and did 
not wish further treatment. Four of these patients had 
rare cataplexy (once or twice a month); 3 were treated 
with modafinil (as monotherapy 400–600 mg/day, or to-
gether (200 mg/day) with venlafaxine 75 mg/day or fluox-
etine 20 mg/day). One patient was treated with clomip-
ramine 100 mg/day. In these patients no follow-up assess-
ment under SO was possible as they discontinued the 
medication shortly after initiation (1 week in most cases).
 Adverse Events 
 The most common adverse event (considering all 18 
patients) was nighttime confusion (n = 6). Others includ-
ed nausea (n = 2), enuresis (n = 2, in 1 of the cases only 
once over 1.5 years), diffuse muscle pain, headache, flat-
ulence, disturbance in attention and forgetfulness (n = 
1). The patient with diffuse muscle pain also had enure-
sis; after a dose reduction from 6 to 4.5 g/day the adverse 
events decreased and the patient insisted on taking the 
medication. Only 1 patient discontinued treatment be-
cause of adverse events. This patient reported pro-
Table 2. E ffect of SO on different subjective and objective parameters
Variable Cases, n Before SO treatment
mean 8 SD
After SO treatment
mean 8 SD
p value
ESS 13 17.881 13.981.2 0.001
Number of cataplexies/month, median 13 20 1 0.001
Number of sleep paralyses/month 13 4.188.3 0 0.011
Number of hallucinations/month 13 7.689.5 0.481.1 0.005
Nightmares/month 13 6.5810.3 1.585.5 NS
Sleep/rest efficiency in actigraphy 8 60.5819.7 7684 0.017
Mean sleep latency in MSLT, min 8 281.5 2.482.6 NS
Number of SOREM in MSLT 8 3.680.5 2.481.4 0.038
Mean sleep latency in MWT, min 9 5.584.5 17.488.9 <0.001
Number of SOREM in MWT 9 181.1 0.481.1 NS
Error % in SCVT 8 10.8 812.5 2.182.1 0.017
Total sleep time in PSG, min 5 390850 398842 NS
Sleep latency in PSG, min 5 11.7816 5.687.5 NS
Sleep efficiency in PSG, % 5 88.587.9 92.185.7 NS
REM latency, min 5 76.68109.4 21.6841.9 NS
NREM-1, % 5 19.185.5 8.282.8 0.071
NREM-2, % 5 38.3810.2 37.589.3 NS
Slow wave sleep, % 5 10.587.7 33.1814.7 0.074
Apnea/hypopnea index/h 5 22.4827.8 16.2816.7 NS
PLMS index/h 5 7.187.2 8.3814.8 NS
Arousal index 5 20.586.3 9.282.3 0.067
E SS = Epworth sleepiness score; MSLT = multiple sleep latency test; MWT = maintenance of wakefulness 
test; SOREM = sleep-onset REM period; SCVT = steer-clear vigilance test.
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nounced nausea and worsening of nighttime sleep and 
cataplexy. 
 There was 1 patient who over time voluntarily in-
creased the dose of SO from 2  ! 4.5 g to 3  ! 4.5 g per 
night because of nighttime sleep disturbance.
 Discussion 
 Efficacy: Clinical Findings 
 SO led to significant improvement of cataplexy, day-
time sleepiness and alertness, sleep paralysis, hallucina-
tions, nightmares and nighttime sleep. Actigraphy and 
SCVT were used for the first time to assess the treatment 
effects of SO.
 Cataplexy improvement regarding its frequency, dura-
tion and severity has been shown in a number of studies 
 [10–12, 21–27, 34] . As already reported by Mamelak et al. 
 [34] , cataplexy under SO occurred later in the day, when 
the patients were tired. Consistent with previous studies 
 [11, 21, 24, 26, 27, 34] , improvement of daytime sleepiness 
and alertness was demonstrated. As 5 patients were treat-
ed with modafinil (in 1 in alternation with methylpheni-
date) and 1 with fluoxetine, the effects on EDS cannot 
only be attributed to SO. Sleep paralysis and hallucina-
tions improved too, as previously reported  [11–13, 34] . In 
more recent studies  [21, 23–25] , a decrease in the frequen-
cy of sleep paralyses and hallucinations was observed, but 
the results did not reach statistical significance. Night-
mares disappeared in 3 of our patients, 1 of them report-
ed that she continued dreaming but the dreams were no 
longer frightening. This phenomenon has also been de-
scribed by Mamelak et al.  [34] . A literature overview of 
different studies, assessing the effects of SO, is presented 
in table 3.
 Efficacy: Actigraphy, MSLT, MWT, SCVT and PSG 
 Actigraphy showed a marked improvement in the 
nighttime rest/sleep efficiency, consistent with the sub-
jectively reported improvement of nighttime sleep. Simi-
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larly, a significant subjective nighttime sleep improve-
ment  [11–13, 34] and a significant decrease in the number 
of nighttime awakenings have been reported  [21, 25] . To 
our knowledge, actigraphy data has not been previously 
used to assess the treatment effects of SO. Actigraphy al-
lows the assessment of sleep-wake patterns over longer 
periods of time. As seen in  figure 2 , the results are com-
parable with the hypnogram, obtained after an overnight 
PSG. We suggest that the method can be a useful, far less 
expensive and less complex tool in the evaluation of the 
treatment effects of SO, especially concerning nighttime 
sleep improvement.
 There were no significant differences in daytime sleep 
latency in MSLT as already reported in the literature  [34] . 
Concordant with previous studies, a significant improve-
ment of the mean sleep latency in MWT was observed 
 [24, 26, 27] . The SCVT demonstrated an improvement in 
sustained attention. This result can be compared to the 
Table 3.  Literature overview
Reference
(first author)
Design Patients
n
Methods EDS/sleep
attacks
Cataplexy Sleep
paralyses
Hallucina-
tions
Nighttime 
sleep quality
Broughton
1979 [10]
case series, open 16 clinical assessment improved improved NA NA improved
Scharf
1985 [11]
case series, open 30 clinical assessment, 
PSG
improved improved improved improved improved
Mamelak
1986 [34]
case series, open 48 clinical assessment, 
PSG, MSLT
improved improved improved improved improved
Scrima
1989 [12]
double-blind,
counter-balanced
crossover design
20 clinical assessment, 
daily diary
not 
significantly 
different
improved NA NA improved
Lammers
1993 [13]
randomized, 
double-blind 
placebo-controlled 
crossover design
24 daily diary, 
questionnaires, 
PSG, MSLT
improved improved, 
but not 
significantly
low 
incidence, 
not accessible
improved improved, 
but not 
significantly
US Xyrem 
Multicenter
Study Group
2002 [21]
multicenter, 
double-blind 
placebo-controlled 
136 daily diary, 
questionnaires
improved, 
dose-
dependent
improved, 
dose-
dependent
improved, 
but not 
significantly
improved, 
but not 
significantly
improved, 
dose-
dependent
US Xyrem 
Multicenter Study 
Group 2003 [23]
open-label 118 daily diary, 
questionnaires
long-term 
improvement
long-term 
improve-
ment
improved, 
but not 
significantly
improved, 
but not 
significantly
improved, 
but not 
significantly
Mamelak
2004 [24]
open-label study 25 PSG, MWT, 
questionnaire
improved improved improved improved improved
Xyrem 
International
Study Group
2005 [25]
double-blind 
placebo-controlled 
228 daily diary NA improved, 
dose-
dependent
improved, 
but not 
significantly
improved, 
but not 
significantly
NA
Xyrem 
International
Study Group
2005 [27]
double-blind 
placebo-controlled 
228 daily diary, 
questionnaires, 
MWT
improved, 
dose-
dependent
NA NA NA NA
Black
2006 [26]
multicenter, 
double-blind 
placebo-controlled 
270 daily diary, 
questionnaires, 
MWT
improved NA NA NA NA
Black
2009 [36]
double-blind 
placebo-controlled 
278 daily diary, 
questionnaires, 
PSG, MWT
improved NA NA NA improved
M SLT = Multiple sleep latency test; MWT = maintenance of wakefulness test; NA = not available; PSG = polysomnography.
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improved ability to stay awake in MWT, but whereas 
MWT requires a whole day of testing, SCVT is completed 
in 30 min. Additionally, it is in a way closer to some ev-
eryday life situations, where patients are involved in mo-
notonous tasks, but their active participation is still re-
quired. We suggest that the test is used complementary 
to MWT.
 SO also leads to changes in nighttime sleep architec-
ture, such as decrease of NREM-1  [24] , increase of slow 
wave sleep  [24, 34] and decrease in nighttime awakenings 
 [21, 24] . As PSG was available in only 5 patients before 
and after treatment, we could not find significant differ-
ences in nighttime sleep parameters. Nevertheless, a 
trend for a decrease in NREM-1 and in the arousal index 
and a trend for increase in slow wave sleep were observed. 
Although not significant, there was a decrease in apnea/
hypopnea index after SO treatment. This finding is in 
line with a recent report in which the use of SO 4.5 g/
night over 2 weeks did not generate respiratory depres-
sant effects in obstructive sleep apnea patients as mea-
sured by the apnea/hypopnea index, obstructive apnea 
events, central apneas, and oxygen saturation  [35] .
 Safety 
 SO was well tolerated in most patients. Consistent with 
the literature  [21, 23, 25] , adverse events primarily affect-
ed the central nervous system and digestive system. In 
most patients, there was no dose relationship for the most 
common adverse events and the majority were mild to 
moderate in severity. In 1 patient, dose reduction led to 
improvement of the adverse events. Only 1 patient dis-
continued the medication because of nausea and worsen-
ing of the narcolepsy symptoms.
 Conclusion 
 SO is effective not only for cataplexy but also for EDS, 
sleep paralyses, hallucinations and nighttime sleep quality 
in NC. The drug is generally well tolerated in spite of the 
occurrence of mild-to-moderate adverse events. Actigra-
phy offers a cheaper and less complex alternative to PSG 
for assessment of SO treatment effects, especially in every-
day practice, and vigilance tests should be used comple-
mentary to MWT in order to assess sustained attention.
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